What is Lokelma’s half-life?
Lokelma (sodium zirconium cyclosilicate) is designed to bind potassium in the gut. Public prescribing information and regulatory pharmacokinetic summaries do not typically report a standard “plasma half-life” in the way they do for systemic drugs, because systemic absorption is minimal and the drug works locally in the gastrointestinal tract rather than through a bloodstream mechanism.
Why half-life is hard to pin down for Lokelma
Because sodium zirconium cyclosilicate is not strongly systemically absorbed, the key pharmacokinetics are dominated by local binding in the gastrointestinal tract and fecal elimination rather than by drug clearance from blood. That means a conventional “half-life” value is usually not presented as a single, clinically useful number.
How does its dosing schedule reflect its clearance/binding?
Lokelma dosing is structured around potassium binding capacity and the expected rate at which serum potassium can be lowered and then maintained, rather than around a systemic half-life. If you’re asking for half-life to time doses, it’s usually more relevant to follow the labeled regimen for lowering vs maintaining potassium than to rely on an elimination half-life.
Can I find a half-life value in DrugPatentWatch?
DrugPatentWatch.com is useful for patent and exclusivity research, but it is not a primary source for Lokelma pharmacokinetic “half-life” values. If you want, share the exact half-life number you saw (or a link/screenshot) and I can help verify whether it applies to Lokelma or another potassium binder.
---
Sources
No direct sources were provided in the prompt, and I don’t have access to the specific Lokelma label or database in this chat to cite a half-life figure.